TickerTalks
Browse all tickers →
TickerTalks›$SYK
SYSYK

Stryker Corporation

$SYK·$113B·Medical - Devices·Healthcare
$298.00+1.1%YTD-21.6%1Y-21.8%
Price updated 6h ago·X counts updated 8d ago
SYSYK
$SYKStryker Corporation
$298.00+1.13%127 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $SYK on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

127X posts · last 7 days
Oct 2Oct 11
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $SYK's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

Bearish sentimentAI analysisGenerated by AI from underlying data7 posts analyzed · as of 2026-09-15

Stryker drops 7-9% after the CFO at Wells Fargo said guidance is only maybe-achievable, with supply constraints hitting peripheral vascular and joint replacement disappointing. Posters describe it as a generalist favorite turned 'shitco', and value hunters wait for RSI <30 to nibble.

Read what X is saying about $SYK

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $SYK — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Proven numbersSelling offAI verdict · as of 2026-10-03

Falling on heavy selling — points lower unless it turns around.

Stryker at 7% of 52w range after the CFO at Wells Fargo said FY26 guidance is only maybe-achievable — supply constraints and peripheral-vascular disappointments are the specific headwinds.

Stryker Corporation is the global medical-devices leader — Orthopaedics and Spine (knees, hips, trauma) plus MedSurg and Neurotechnology (electrophysiology, endoscopy). The stock has lost 22% YTD, now at 7% of its 52-week range after the CFO walked back FY26 guidance.

  • Growth is still positive: Q1 2026 revenue of $6.0B at +2.6% YoY after +11.4% in Q4 — the growth deceleration is specifically on supply constraints hitting peripheral vascular, with joint replacement also disappointing.
  • Earnings beats were coasting until Q1: last four prints at +6%, -13%, +1.6%, +1.9% — the Q1 2026 miss was the first visible crack, with the CFO's "guidance is only maybe-achievable" at Wells Fargo converting it into a formal downgrade.
  • The securities-litigation chatter from Block & Leviton and the Hagens Berman peripheral-vascular disclosure framing is the live overhang — operational optics are the worst they've been in years for the company.

An Oct 29 Q3 print with peripheral-vascular supply constraints quantified plus a clean FY26 guide restarts the thesis; another peripheral-vascular miss or a joint replacement guide cut and the breakdown continues toward $250.

Agrees with X sentimentX is bearish on the Wells Fargo CFO walkback — "generalist favorite turned shitco" is harsh but the mechanics (-13% Q4 2026 miss, Q1 2026 revenue decelerating to +2.6%) back the view. The value-hunters-wait-for-RSI-<30 framing is honest; the operational optics have deteriorated materially.

What to watch: Oct 29 Q3 earnings — peripheral-vascular supply-constraint quantification, joint-replacement organic growth, FY26 guide refresh, and any update on the ongoing securities-litigation discovery. A clean guide plus supply-constraint resolution re-rates it; another peripheral-vascular miss cements the breakdown.

On the calendar: 2026-10-29 — Q3 2026 earnings

Read the AI verdict on $SYK

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Medical technology company specializing in orthopedic implants, surgical robots (Mako), and emergency equipment across 75+ countries.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Devices sits in its cycle right now — and what that implies for $SYK.

Medical - Devices · Healthcare

Aging population demographics and AI-assisted device adoption (smart implants, continuous glucose monitors, digital health integration) are the long-cycle structural drivers. Reimbursement timing for new modalities (CMS coverage decisions) and procedure volume recovery from COVID-era deferred care shape the 2026 revenue trajectory.

What this means for $SYK

Partial — Medical technology company specializing in orthopedic implants, surgical robots (Mako), and emergency equipment across 75+ countries.

Industry benchmark

21-name peer basket
+11.1%YTD
+0.5%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
36.6How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
9.6%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
21.3%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
3.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
4.9Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
15.1%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
63.7%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.7Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 30, 2026$3.69$3.49+5.7%
Q1 2026Apr 30, 2026$2.60$2.98-12.8%
Q4 2025Jan 29, 2026$4.47$4.40+1.6%
Q3 2025Oct 30, 2025$3.19$3.13+1.9%
Next earningsThu, Oct 29·consensus EPS $3.55

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$6.0B+2.6%63.3%15.5%$1.95$415.0M
Q4 FY25$7.2B+11.4%65.2%27.3%$2.21$1.9B
Q3 FY25$6.1B+10.2%63.6%18.7%$2.25$1.4B
Q2 FY25$6.0B+11.1%62.3%22.6%$2.32$928.0M

Forward consensus

5-year forecast · up to 22 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$27.2B$26.9B – $27.4B$14.96$14.90 – $15.0620
FY27$29.5B$28.7B – $29.9B$16.68$16.12 – $17.1520
FY28$31.9B$31.2B – $32.5B$18.59$17.41 – $19.3922
FY29$34.8B$33.7B – $35.8B$20.75$19.96 – $21.5814
FY30$37.6B$36.5B – $38.8B$23.05$22.16 – $23.9711

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.0×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.25%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-0.4%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-8.7%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 348.1M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.9% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.785-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 21Crotty Dylan BramPresident441 sh$145KSellAug 19Ronda E StrykerDirector50.0K sh$17.0MSellAug 18Ronda E StrykerDirector300.0K sh$100.8MSellAug 18Debra KingSee Remarks826 sh$278KSellMay 28Robert S FletcherVP, Chief Legal Officer4.5K sh$1.4MSellMay 26Ronda E StrykerDirector25.5K sh$7.9MSellMay 11Fink M KathrynVP, Chief HR Officer8.7K sh$2.5M
+ 21 other (11 awards · 5 inkinds · 3 others · 1 gift · 1 exempt) in window

See when $SYK insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KOfficer or director changeOct 68-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
3New insider — initial holdingsSep 83
AI summary

Stryker Corporation filed an initial Form 3 for Emily Kay Baculik, reporting initial beneficial ownership upon her appointment as VP Corporate Controller and Principal Accounting Officer, with an event date of September 1, 2026. The filing discloses that Baculik directly owns 1,534 shares of Stryker common stock and holds derivative securities such as stock options. The Form 3 is required under Section 16(a) of the Securities Exchange Act of 1934.

8-KOfficer or director changeMay 208-K — Item 5.02: Officer or director change
AI summary

Stryker announced that VP and Chief Accounting Officer William E. Berry, Jr. will retire September 1, 2026, with Emily Baculik (age 46), VP Corporate Controller since November 2024, succeeding him as chief accounting officer on the same date. The planned transition ensures continuity in financial reporting oversight for the global medical technology company.

8-KShareholder voteMay 88-K — Item 5.07: Shareholder vote
+ 7 other (2 10-Qs · 2 earnings 8-Ks · 1 routine 8-K · 1 SD) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

2 Industries Beyond AI With Long-Term Demand Drivers for 2027zacks.com·11h agoStryker Enters Soft-Tissue Robotics With $400 Million CMR Dealzacks.com·15h agoSecurities Fraud Investigation Into Stryker Corporation (SYK) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firmglobenewswire.com·5d agoINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYKprnewswire.com·5d agoStryker Corporation (SYK) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigationglobenewswire.com·5d ago

More in Medical - Devices

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$TMDX$MDT$QSI$BIO$ABT$PACB$BSX$BFLY
Voices on X · last 7 days

No standout posts about $SYK on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport